High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults

Paolo Pedrazzoli, J. A. Ledermann, J. P. Lotz, S. Leyvraz, M. Aglietta, G. Rosti, K. M. Champion, S. Secondino, F. Selle, N. Ketterer, G. Grignani, S. Siena, T. Demirer

Research output: Contribution to journalArticlepeer-review

Abstract

Since the early 1980s high dose chemotherapy with autologous hematopoietic stem cell support was adopted by many oncologists as a potentially curative option for solid tumors, supported by a strong rationale from laboratory studies and apparently convincing results of early phase II studies. As a result, the number and size of randomized trials comparing this approach with conventional chemotherapy initiated (and often abandoned before completion) to prove or disprove its value was largely insufficient. In fact, with the possible exception of breast carcinoma, the benefit of a greater escalation of dose of chemotherapy with stem cell support in solid tumors is still unsettled and many oncologists believe that this approach should cease. In this article, we critically review and comment on the data from studies of high dose chemotherapy so far reported in adult patients with small cell lung cancer, ovarian cancer, germ cell tumors and sarcomas.

Original languageEnglish
Pages (from-to)1479-1488
Number of pages10
JournalAnnals of Oncology
Volume17
Issue number10
DOIs
Publication statusPublished - Oct 2006

Keywords

  • High dose chemotherpy
  • Solid tumors
  • Stem cell transplantation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults'. Together they form a unique fingerprint.

Cite this